Milestone Pharmaceuticals (MIST) EBT Margin (2021 - 2022)

Milestone Pharmaceuticals (MIST) posted EBT Margin of 1002.0% for Q3 2022, down 19619.48% on a QoQ basis from 5.13% in Q2 2021.

Milestone Pharmaceuticals (MIST) EBT Margin (2021 - 2022) Analysis & Trends

Milestone Pharmaceuticals' EBT Margin history runs 2 years deep, the most recent figure standing at 1002.0% for Q3 2022.

  • Quarterly EBT Margin changed N/A year-over-year to 1002.0% in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 381.48% (changed N/A YoY) and the FY2021 annual result came in at 285.69%, changed N/A from the prior year.
  • EBT Margin was 1002.0% for Q3 2022 at Milestone Pharmaceuticals, down from 5.13% in the prior quarter.
  • Across five years, EBT Margin topped out at 5.13% in Q2 2021 and bottomed at 1002.0% in Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 17.13%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 41.95%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 23.05%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 34.77%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Milestone Pharmaceuticals 156.34 Mn -27.87 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2022 -1,002.00%
Jun 30, 2021 5.13%